Ultragenyx Pharmaceutical's market cap is currently ―. The company's EPS TTM is $; its P/E ratio is ―; Ultragenyx Pharmaceutical is scheduled to report earnings on August 1, 2024, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22
Income Statement	-
Total Revenue	$ 127.39M	$ 98.05M	$ 46.33M	$ 100.50M	$ 103.35M
Gross Profit	$ 127.39M	$ 98.05M	$ 108.31M	$ 100.50M	$ 60.33M
EBIT	-	$ -159.00M	$ -159.10M	$ -163.48M	$ -173.99M
EBITDA	-	-	$ -156.95M	$ -161.24M	$ -180.04M
Net Income Common Stockholders	$ -123.19M	$ -120.01M	$ -159.83M	$ -163.97M	$ -151.83M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 577.21M	$ 442.09M	$ 551.98M	$ 629.35M	$ 747.76M
Total Assets	$ 1.49B	$ 1.24B	$ 1.31B	$ 1.38B	$ 1.29B
Total Debt	$ 0.00	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Net Debt	$ -577.21M	$ -442.09M	$ -551.98M	$ -629.35M	$ -747.76M
Total Liabilities	$ 1.22B	$ 1.21B	$ 1.18B	$ 1.16B	$ 1.55B
Stockholders Equity	$ 275.41M	$ 31.71M	$ 129.03M	$ 220.48M	$ 352.49M
Cash Flow	-
Free Cash Flow	-	-	$ -132.60M	$ -181.90M	$ -117.31M
Operating Cash Flow	$ -83.90M	$ -117.87M	$ -116.16M	$ -156.87M	$ -90.34M
Investing Cash Flow	$ -107.02M	$ 64.30M	$ 99.42M	$ 111.30M	$ -171.60M
Financing Cash Flow	$ 330.61M	$ 25.23M	$ 33.01M	$ -722.00K	$ 1.88M

Currency in USD

Ultragenyx Pharmaceutical Earnings and Revenue History

Income Statement >

Ultragenyx Pharmaceutical Debt to Assets

Balance Sheet >

Ultragenyx Pharmaceutical Cash Flow

Cash Flow >

Ultragenyx Pharmaceutical Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing